Wegovy Side Effects: What Patients Should Know

Wegovy (semaglutide) is a prescription GLP-1 receptor agonist, and its most commonly reported side effects involve the gastrointestinal system, including nausea, diarrhea, vomiting, constipation, and abdominal discomfort.

These symptoms are especially relevant during dose escalation and are often mild to moderate, but some gastrointestinal or other symptoms can require medical evaluation.

This article explains the most commonly reported Wegovy side effects, why they may occur, and which symptoms should be discussed promptly with a healthcare professional.

Important: Side-effect rates can differ depending on the Wegovy formulation, dose, patient population, and indication. Unless otherwise stated, the percentages below refer to clinical trials of Wegovy 2.4 mg once-weekly subcutaneous injection in adults with obesity or overweight.

Why Can Wegovy Cause Gastrointestinal Side Effects?

Wegovy affects appetite regulation and also delays gastric emptying, which helps explain why gastrointestinal symptoms are among its most frequently reported adverse effects.

Semaglutide acts as an agonist at the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 receptors are involved in appetite and calorie-intake regulation, and semaglutide can reduce calorie intake.

The FDA prescribing information also states that semaglutide delays gastric emptying.

These effects can contribute to symptoms such as nausea, fullness, bloating, vomiting, constipation, or diarrhea in some patients.

Gastrointestinal symptoms have been reported most frequently during dosage escalation. The prescribed Wegovy dosing schedule gradually increases the dose, in part to reduce the risk of gastrointestinal adverse reactions.

Patients should not independently change their prescribed dose or dosing schedule because of side effects. Persistent or significant symptoms should instead be discussed with the prescribing healthcare professional.

What Are the Most Common Wegovy Side Effects?

Nausea is the most frequently reported Wegovy side effect, but diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue are also common.

In pooled clinical trials involving 2,116 adults receiving Wegovy 2.4 mg once weekly for weight reduction, the following adverse reactions were reported:

Source: U.S. Wegovy Prescribing Information, clinical trials in adults with obesity or overweight receiving Wegovy 2.4 mg injection.

Overall, gastrointestinal adverse reactions were reported in approximately 73% of Wegovy-treated adults compared with 47% of placebo-treated adults in these weight-reduction trials.

Severe gastrointestinal reactions were much less common but occurred more frequently with Wegovy than placebo: 4.1% versus 0.9%, respectively.

Clinical trial percentages should not be interpreted as predicting what will happen to an individual patient.

Does Nausea Usually Continue Throughout Treatment?

Clinical trials suggest that gastrointestinal Wegovy side effects are often most noticeable during dose escalation rather than remaining equally intense throughout treatment.

In the STEP 1 trial, gastrointestinal disorders—including nausea, diarrhea, vomiting, and constipation—were the most frequently reported adverse events with semaglutide. Most were described as mild to moderate and transient.

However, tolerability varies substantially between individuals.

Persistent nausea, repeated vomiting, difficulty maintaining fluid intake, or symptoms that interfere with normal daily activities should not simply be assumed to be an expected part of treatment.

They should be discussed with the prescribing healthcare professional.

When Do Wegovy Side Effects Need Medical Attention?

Persistent, severe, or unusual symptoms deserve more attention than temporary mild gastrointestinal discomfort.

Several important adverse reactions and warnings are included in the Wegovy prescribing information.

Pancreatitis

Acute pancreatitis has been observed in patients receiving GLP-1 receptor agonists, including Wegovy.

Persistent or severe abdominal pain—particularly pain that may radiate toward the back, with or without nausea or vomiting—requires prompt medical assessment.

The FDA labeling advises discontinuation of Wegovy if pancreatitis is suspected and appropriate medical management is initiated.

Gallbladder Problems

Wegovy treatment has been associated with gallstones and gallbladder inflammation.

In adult weight-reduction trials, gallstones were reported in 1.6% of patients receiving Wegovy injection versus 0.7% receiving placebo, while cholecystitis occurred in 0.6% versus 0.2%, respectively.

Substantial or rapid weight loss itself can increase the risk of gallstones, although the prescribing information reports a higher incidence of acute gallbladder disease with Wegovy even after accounting for the degree of weight loss.

Upper abdominal pain, fever, jaundice, or other symptoms suggestive of gallbladder disease should be medically evaluated.

Dehydration and Kidney Problems

Repeated vomiting or diarrhea can cause dehydration.

The Wegovy prescribing information includes reports of acute kidney injury associated with volume depletion, particularly in patients experiencing gastrointestinal symptoms such as prolonged nausea, vomiting, or diarrhea.

Patients who cannot maintain adequate hydration or who experience persistent gastrointestinal symptoms should contact their healthcare provider.

Severe Gastrointestinal Symptoms

Severe gastrointestinal adverse reactions can occur.

Wegovy is not recommended in patients with severe gastroparesis according to the current U.S. prescribing information.

Persistent vomiting, severe abdominal symptoms, or inability to eat or drink normally warrants medical review rather than continued self-management.

Hypoglycemia

Wegovy can lower blood glucose.

The risk of hypoglycemia is particularly relevant for people with diabetes who are also receiving insulin or medications that stimulate insulin secretion, such as sulfonylureas.

Diabetes medications may therefore require individualized monitoring or adjustment by the treating clinician.

Allergic Reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.

Symptoms such as difficulty breathing or significant swelling of the face, lips, tongue, or throat require urgent medical attention.

What About the Thyroid Cancer Warning?

Wegovy carries a boxed warning concerning thyroid C-cell tumors, but the human risk has not been established.

Semaglutide caused thyroid C-cell tumors in rodent studies. It remains unknown whether Wegovy causes medullary thyroid carcinoma (MTC) in humans.

Wegovy is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

A neck mass, persistent hoarseness, difficulty swallowing, or difficulty breathing should be discussed with a healthcare professional.

What Should Patients Know Before Surgery or Sedation?

Patients taking Wegovy should tell their medical team before procedures requiring general anesthesia or deep sedation.

Because Wegovy delays gastric emptying, rare postmarketing cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists during procedures involving general anesthesia or deep sedation.

Current FDA labeling states that available evidence is insufficient to establish a single strategy for changing fasting instructions or temporarily discontinuing Wegovy before procedures.

For this reason, patients should inform the surgeon, anesthesiologist, and prescribing clinician that they are taking Wegovy and follow individualized medical instructions.

Benefits and Limitations Should Be Considered Together

Understanding Wegovy means considering both its potential clinical effects and its safety profile.

In clinical trials, semaglutide has produced clinically meaningful weight reduction in appropriately selected patients. At the same time, gastrointestinal symptoms are common, and less frequent but clinically important adverse reactions—including pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, and hypersensitivity—require appropriate monitoring.

The appropriate treatment decision therefore depends on the patient's medical history, other medications, treatment goals, tolerability, and ongoing clinical supervision.

Wegovy is a prescription medicine and should be used under the care of a licensed healthcare professional.

Frequently Asked Questions About Wegovy Side Effects

1. What is the most common Wegovy side effect?

Nausea is the most commonly reported adverse reaction with Wegovy. In pooled adult clinical trials of the 2.4 mg weekly injection, nausea was reported by 44% of Wegovy-treated patients compared with 16% of placebo-treated patients. Individual experience can differ substantially.

2. Are diarrhea and constipation both possible with Wegovy?

Yes. Both diarrhea and constipation have been reported with Wegovy. In adult 2.4 mg injection trials, diarrhea occurred in 30% and constipation in 24% of Wegovy-treated patients. GLP-1 medications can affect gastrointestinal function in different ways between individuals.

3. Why does Wegovy cause nausea?

Wegovy influences appetite regulation and delays gastric emptying, which may contribute to nausea and other gastrointestinal symptoms. These symptoms have been reported particularly during dose escalation. Persistent or severe nausea should be discussed with the prescribing clinician.

4. Can Wegovy cause serious stomach problems?

Severe gastrointestinal adverse reactions can occur, although they are much less common than mild-to-moderate gastrointestinal symptoms. In adult weight-reduction trials, severe gastrointestinal reactions occurred in 4.1% of patients receiving Wegovy injection compared with 0.9% receiving placebo. Wegovy is not recommended in patients with severe gastroparesis under the current U.S. label.

5. Can Wegovy affect the gallbladder or pancreas?

Yes, gallbladder disease and acute pancreatitis are included in the Wegovy safety information. Persistent or severe abdominal pain, particularly pain radiating to the back, or symptoms such as jaundice or fever require prompt medical assessment.

6. Can vomiting or diarrhea from Wegovy become dangerous?

Persistent vomiting or diarrhea can lead to dehydration and, in some cases, kidney injury. Patients who cannot maintain fluid intake or who experience prolonged gastrointestinal symptoms should contact a healthcare professional rather than assuming the symptoms are harmless.

7. Does Wegovy have the same side effects for everyone?

No. Side effects vary according to the individual, dose, formulation, medical history, other medications, and stage of dose escalation. Clinical trial percentages describe groups of patients and cannot predict an individual patient's experience.

8. Should I stop Wegovy if I experience side effects?

Treatment decisions should usually be made with the prescribing healthcare professional rather than by independently changing the dose or schedule. Severe symptoms—including severe or persistent abdominal pain, significant dehydration, or signs of a serious allergic reaction—require prompt medical assessment.

Disclaimer

This content is for general educational purposes only and is not medical advice. Wegovy is prescription-only and must be prescribed by a licensed healthcare professional. Approval status, approved indications, formulations, dosages, and availability vary by country. Always consult local regulatory guidance and a qualified physician before making treatment decisions.

Regulatory and safety information reflects information available at publication and may change. Verify current information with the relevant national regulatory authority.

References

1. U.S. National Library of Medicine. DailyMed: Wegovy (semaglutide) Prescribing Information. Updated June 18, 2026. -> Wegovy U.S. Prescribing Information — DailyMed
   
   
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. doi:10.1056/NEJMoa2032183. -> STEP 1 Trial — New England Journal of Medicine